Several pharmaceutical industry giants, including Bristol Myers Squibb, Johnson & Johnson, Novartis, and Novo Nordisk, brought a team of lawyers to a courtroom in Trenton, New Jersey, to challenge Medicare’s new drug price negotiation program. The program, part of the Inflation Reduction Act, allows Medicare to negotiate drug prices starting in 2026. The lawyers argued against various aspects of the law and how it has been interpreted. This case could be a significant test for arguments that have not been addressed in other states where similar challenges are taking place. The outcome could have major implications for the pharmaceutical industry.
Source link
Medicare drug price negotiation hearing pits pharma v Biden admin
